Results 61 to 70 of about 22,935 (284)

Mechanisms of the glycaemic effects of sulfonylureas.

, 1996
Sulfonylureas are widely used to treat non-insulin dependent diabetes mellitus. These drugs exert their hypoglycaemic effects by stimulating insulin secretion from the pancreatic beta-cell.
Ashcroft, FM, Ashcroft, Frances
core   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Class-Specific Immunochromatographic Assay Enabled by Mesoporous Nanozyme-Catalyzed Signal Amplification for On-Site Screening of Sulfonylureas

Foods
Conventional immunochromatographic assays (ICAs) face limitations in sensitivity and dynamic range, hindering their application in on-site, class-specific screening of sulfonylurea (SU) adulteration in functional foods.
Yanting Li, Zixian He, Pengjie He, Zixuan Tang, Esra Bağda, Efkan Bağda, Zhenlin Xu, Xiangmei Li   +7 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells.

, 1996
Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic beta cells. The molecular mechanisms involved are not fully understood but are believed to involve inhibition of ...
Berggren, PO, Chibalin, Alexander, Eliasson, Lena, Renström, E, Eliasson, L, Rhodes, Christopher J., Deeney, Jude T., Berggren, Per-Olof, Gabel, Jakob, Larsson, Olof, Rhodes, CJ, Gromada, J, Lindström, P, Flatt, Peter R., Gäbel, J, Ammala, Carina, Renström, Erik, Deeney, JT, Rorsman, Patrik, Bertorello, Alejandro M., Larsson, O, Ammälä, C, Chibalin, A, Bokvist, K, Flatt, PR, Gromada, Jesper, Bertorello, AM, Bokvist, Krister, Lindstrom, Per   +28 more
core   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Preparation of Unsymmetrical Sulfonylureas from N,N‘-Sulfuryldiimidazoles

, 2016
The synthetic methods reported in the literature for the preparation of sulfonylureas tend to be restricted in scope or unsuitable for use in parallel synthesis.
Kenneth E. Kinsey (3033828), James F. Burns (2322715), Serge Beaudoin (3033831)   +2 more
core   +1 more source

Organelle‐Resolved Tetrazine‐trans‐Cyclooctene Click Chemistry for Cargo Delivery and Release

Chemistry – A European Journal, EarlyView.
Bioorthogonal click chemistry tools provide a means for specific intracellular conjugation of molecules. In this study, we used reactive tetrazine (Tz) and TCO moieties for labeling of organelles and organelle‐specific delivery and activation of doxorubicin prodrugs.
Oleh Durydivka, Marek Chovanec, Rastislav Dzijak, Michal Rahm, Jachym Hrusak, Paul E. Reyes‐Gutierrez, Milan Vrabel   +6 more
wiley   +1 more source

Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy

Frontiers in Medicine
Maturity-onset diabetes of the young (MODY) is a rare, genetically heterogeneous form of diabetes characterized by early-onset dysglycaemia, typically before 25 years of age, and autosomal dominant inheritance.
Chiara Gulisano, Concetta Aloi, Alessandro Salina, Camilla Marazzi, Giordano Spacco, Serena Cappato, Renata Bocciardi, Renata Bocciardi, Dario Iafusco, Giacomo Tantari, Giuseppe d'Annunzio, Nicola Minuto, Mohamad Maghnie, Marta Bassi, Francesca Faravelli   +14 more
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source